Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study

Ekaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, Nicolas Frey, Michael Brewster, Günter Fingerle-Rowson, Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, Nicolas Frey, Michael Brewster, Günter Fingerle-Rowson, Candice Jamois

Abstract

Aims: Rituximab is standard care in a number of lymphoma subtypes, including follicular lymphoma (FL), although many patients are resistant to rituximab, or develop resistance with repeated treatment, and a high proportion relapse. Obinutuzumab is a novel anti-CD20 monoclonal antibody with improved efficacy over rituximab. It is approved for previously untreated chronic lymphocytic leukaemia (CLL), and for use with bendamustine in patients with rituximab-relapsed/refractory FL.

Methods: Using a previously described population pharmacokinetic (PK) model of obinutuzumab in patients with non-Hodgkin lymphoma and CLL, we conducted an exposure-response analysis using data from 6 clinical trials in patients with CD20+ B-cell malignancies (CLL11, GADOLIN, GATHER, GAUDI, GAUGUIN and GAUSS) to describe the PK properties of obinutuzumab, identify covariates influencing exposure, and explore how exposure affects safety, efficacy and pharmacodynamics.

Results: A 2-compartment model with linear and time-dependent clearance described obinutuzumab PK. Disease type and subtype, body weight, baseline tumour size, and sex had the largest effects on PK. Obinutuzumab exposure was not associated with occurrence or severity of adverse events, but higher exposure appeared to be associated with greater efficacy, particularly longer progression-free survival. However, in multivariate Cox regression analysis, progression-free survival benefit in the obinutuzumab plus bendamustine arm was independent of exposure.

Conclusion: The updated population PK model reported here accurately describes the PK of obinutuzumab patients with non-Hodgkin lymphoma and CLL. The selected obinutuzumab dosing regimen offers clinical benefit in a majority of rituximab-refractory FL patients treated with bendamustine, irrespective of variability in exposure, whilst minimising adverse events.

Trial registration: ClinicalTrials.gov NCT01010061 NCT01059630 NCT01414855 NCT00825149 NCT00517530 NCT00576758.

Keywords: drug exposure; follicular lymphoma; obinutuzumab; pharmacokinetics.

Conflict of interest statement

The authors declare the following conflicts of interest: E.G. and L.G. were consultants for F. Hoffmann‐La Roche Ltd, and V.B., N.F., M.B. and C.J. are employees of F. Hoffmann‐La Roche Ltd. G.F‐.R. is a former employee of F. Hoffman‐La Roche. G.F.‐R. owns stock in F. Hoffmann‐La Roche Ltd.

© 2019 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Figures

Figure 1
Figure 1
Relationships between PFS and obinutuzumab exposure (Cmean) in patients with FL participating in GADOLIN who received at least 3 dosing cycles of obinutuzumab (n = 128). Lines inside boxes denote medians. Boxes denote IQR. Error bars: limits of 1.5 × IQR. Circles show outliers. Cmean: mean obinutuzumab exposure over induction period; FL: follicular lymphoma, IQR: interquartile range; PFS: progression‐free survival
Figure 2
Figure 2
Covariate effects on HR in the final cox proportional hazards model for PFS (n = 128) in patients with FL participating in GADOLIN who received at least 3 dosing cycles of obinutuzumab (combined with bendamustine). BMINV: bone marrow involvement at baseline; CI: confidence interval; Cmean: mean obinutuzumab exposure over induction period; FL: follicular lymphoma; HR: hazard ratio; PFS: progression‐free survival
Figure 3
Figure 3
Kaplan–Meier plot, showing relationship between PFS (n = 128) and obinutuzumab exposure (by tertiles of Cmean) in patients with FL participating in GADOLIN who received at least 3 dosing cycles of obinutuzumab (combined with bendamustine). The upper table shows HR for PFS in obinutuzumab plus bendamustine arm relative to control arm (n = 166; bendamustine monotherapy) from the final CPH model. Cmean tertile ranges: lower, 141–313 μg/mL; middle, 313–400 μg/mL; higher, 400–794 μg/mL. CI: confidence interval; Cmean: mean obinutuzumab exposure over induction period; FL: follicular lymphoma; HR: hazard ratio; PFS: progression‐free survival

References

    1. Bai B, Huang HQ. Individualized management of follicular lymphoma. Chin Clin Oncol. 2015;4:7.
    1. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1–2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981–987.
    1. Nowakowski GS, Ansell SM. Therapeutic targeting of microenvironment in follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2014;2014:169–173.
    1. Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7:58.
    1. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first‐line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417–1423.
    1. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced‐stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low‐grade lymphoma study group. Blood. 2005;106(12):3725–3732.
    1. Herold M, Haas A, Srock S, et al. Rituximab added to first‐line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an east German study group hematology and oncology study. J Clin Oncol. 2007;25(15):1986–1992.
    1. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.
    1. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low‐grade lymphoma study group. Blood. 2004;104(10):3064–3071.
    1. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non‐Hodgkin's lymphoma: long‐term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853–2858.
    1. Solimando AG, Ribatti D, Vacca A, et al. Targeting B‐cell non Hodgkin lymphoma: new and old tricks. Leuk Res. 2016;42:93–104.
    1. Zappasodi R, de Braud F, Di Nicola M. Lymphoma immunotherapy: current status. Front Immunol. 2015;6:448.
    1. Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011;118(2):358–367.
    1. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti‐CD20 antibody with enhanced direct and immune effector cell‐mediated B‐cell cytotoxicity. Blood. 2010;115(22):4393–4402.
    1. Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2012;5(1):22–33.
    1. Salles GA, Morschhauser F, Solal‐Celigny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non‐Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2920–2926.
    1. Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti‐CD20 monoclonal antibody obinutuzumab (GA101) in B‐cell lymphoma patients. Blood. 2012;119(22):5126–5132.
    1. Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b‐cell lymphoma or mantle‐cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2912–2919.
    1. Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20‐positive B‐cell malignancies. Blood. 2012;119(22):5118–5125.
    1. Kamisoglu K, Phipps A, Jamois C, et al. Greater efficacy and potency of obinutuzumab compared with rituximab in chronic lymphocytic leukemia patients confirmed by a semi‐mechanistic pharmacokinetic/pharmacodynamic model. Blood. 2017;130(1):1267.
    1. Gibiansky E, Gibiansky L, Carlile DJ, et al. Population pharmacokinetics of Obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non‐Hodgkin's lymphoma and exposure‐response in CLL. CPT Pharmacometrics Syst Pharmacol. 2014;3:e144.
    1. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110.
    1. Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122(7):1137–1143.
    1. Salles GA, Morschhauser F, Solal‐Céligny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non‐Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2920–2926.
    1. Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B‐cell non‐Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015;33(30):3467–3474.
    1. Cheson BD, Trnĕný M, Bouabdallah K, et al. Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab‐refractory indolent non‐Hodgkin lymphoma: updated results of the GADOLIN study. Blood. 2016;128(22):615.
    1. Sharman JP, Forero‐Torres A, Costa LJ, et al. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B‐cell lymphoma: the phase II GATHER study. Leuk Lymphoma. 2019;60(4):894–903.
    1. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481–504.
    1. Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab‐refractory indolent non‐Hodgkin lymphoma (GADOLIN): a randomised, controlled, open‐label, multicentre phase 3 trial. Lancet Oncol. 2016;17(8):1081–1093.
    1. Cheson BD, Trask PC, Gribben JG, et al. Health‐related quality of life and symptoms in patients with rituximab‐refractory indolent non‐Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. Ann Hematol. 2017;96(2):253–259.
    1. Gibiansky L, Gibiansky E, Bauer R. Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target‐mediated drug disposition model. J Pharmacokinet Pharmacodyn. 2012;39(1):17–35.
    1. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28(2):171–192.
    1. Brendel K, Comets E, Laffont C, Laveille C, Mentré F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23(9):2036–2049.
    1. Mentre F, Escolano S. Prediction discrepancies for the evaluation of nonlinear mixed‐effects models. J Pharmacokinet Pharmacodyn. 2006;33(3):345–367.
    1. Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N. Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non‐Hodgkin's lymphoma and exposure–response in CLL. CPT Pharmacometrics Syst Pharmacol. 2014. Oct;3:e144.
    1. Harding SD, Sharman JL, Faccenda E, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids Res. 2018;46:D1091‐D1106.
    1. Alexander SPH, Kelly E, Marrion NV, et al. The Concise Guide to PHARMACOLOGY 2017/18: Overview. Br J Pharmacol. 2017;174(Suppl 1):S1–S16.
    1. Li J, Zhi J, Wenger M, et al. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol. 2012;52(12):1918–1926.
    1. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti‐CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005;45(7):792–801.
    1. Yin A, Li J, Hurst D, Visich J. Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non‐Hodgkin's lymphoma. J Clin Oncol. 2010;28(Suppl 15):e13108.
    1. Lim SH, Vaughan AT, Ashton‐Key M, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011;118(9):2530–2540.
    1. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507.
    1. Gibson CR, Sandu P, Hanley WD. Monoclonal antibody pharmacokinetics and pharmacodynamics In: An Z, ed. Therapeutic monoclonal antibodies: from bench to clinic. New Jersey (NJ): John Wiley & Son, Inc; 2009: pp 439–60. John Wiley & Son, Inc.: Hoboken, NJ.
    1. Cartron G, Hourcade‐Potelleret F, Morschhauser F, et al. Rationale for optimal obinutuzumab/GA101 dosing regimen in B‐cell non‐Hodgkin lymphoma. Haematologica. 2016;101(2):226–234.
    1. Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex‐related fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003;197(3):315–322.
    1. Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology. 2013;2(10):e26333.
    1. Tout M, Casasnovas O, Meignan M, et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood. 2017;129(19):2616–2623.
    1. Kaagedal M, Claret L, Marchard M, et al. Herceptin in HER2‐positive gastric cancer: evaluation of exposure‐response with two dose levels. Population Approach Group in Europe (PAGE) 2017; 26: Abstract 7329.
    1. Solal‐Celigny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol. 2010;92(2):246–254.
    1. Solal‐Celigny P, Lepage E, Brousse N, et al. Doxorubicin‐containing regimen with or without interferon alfa‐2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial. J Clin Oncol. 1998;16(7):2332–2338.
    1. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–4562.
    1. Clinical study data request. Available from: . Accessed April 2019.
    1. Clinical study data request: Roche sponsor specific details. Available from: . Accessed April 2019.
    1. Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents. Available from: . Accessed April 2019.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit